OBJECTIVE: To study the membrane expression of endothelial protein C receptor (mEPCR) in the renal microvasculature in lupus nephritis (LN) as a potential marker of injury and/or prognostic indicator for response to therapy. METHODS: mEPCR expression was analysed by immunohistochemistry in normal kidney and in 59 biopsies from 49 patients with LN. Clinical parameters were assessed at baseline, 6 months and 1 year. RESULTS: mEPCR was expressed in the medulla, arterial endothelium and cortical peritubular capillaries (PTCs) in all biopsies with LN but not in the cortical PTCs of normal kidney. Positive mEPCR staining in >25% of the PTCs was observed in 16/59 biopsies and associated with poor response to therapy. Eleven (84.6%) of 13 patients with positive staining for mEPCR in >25% of the PTCs and follow-up at 6 months did not respond to therapy, compared with 8/28 (28.6%) with mEPCR staining in < or =25% PTCs, P = 0.0018. At 1 year, 10 (83.3%) of 12 patients with positive mEPCR staining in >25% of the PTCs did not respond to therapy (with two progressing to end-stage renal disease) compared with 8/24 (33.3%) with positive staining in < or =25% of the PTCs, P = 0.0116. Although tubulo-interstitial damage (TID) was always accompanied by mEPCR, this endothelial marker was extensively expressed in the absence of TID suggesting that poor response could not be attributed solely to increased TID. mEPCR expression was independent of International Society of Nephrology/Renal Pathology Society class, activity and chronicity indices. CONCLUSION: Increased mEPCR expression in PTCs may represent a novel marker of poor response to therapy for LN.
OBJECTIVE: To study the membrane expression of endothelial protein C receptor (mEPCR) in the renal microvasculature in lupus nephritis (LN) as a potential marker of injury and/or prognostic indicator for response to therapy. METHODS: mEPCR expression was analysed by immunohistochemistry in normal kidney and in 59 biopsies from 49 patients with LN. Clinical parameters were assessed at baseline, 6 months and 1 year. RESULTS: mEPCR was expressed in the medulla, arterial endothelium and cortical peritubular capillaries (PTCs) in all biopsies with LN but not in the cortical PTCs of normal kidney. Positive mEPCR staining in >25% of the PTCs was observed in 16/59 biopsies and associated with poor response to therapy. Eleven (84.6%) of 13 patients with positive staining for mEPCR in >25% of the PTCs and follow-up at 6 months did not respond to therapy, compared with 8/28 (28.6%) with mEPCR staining in < or =25% PTCs, P = 0.0018. At 1 year, 10 (83.3%) of 12 patients with positive mEPCR staining in >25% of the PTCs did not respond to therapy (with two progressing to end-stage renal disease) compared with 8/24 (33.3%) with positive staining in < or =25% of the PTCs, P = 0.0116. Although tubulo-interstitial damage (TID) was always accompanied by mEPCR, this endothelial marker was extensively expressed in the absence of TID suggesting that poor response could not be attributed solely to increased TID. mEPCR expression was independent of International Society of Nephrology/Renal Pathology Society class, activity and chronicity indices. CONCLUSION: Increased mEPCR expression in PTCs may represent a novel marker of poor response to therapy for LN.
Authors: X Ye; K Fukudome; N Tsuneyoshi; T Satoh; O Tokunaga; K Sugawara; H Mizokami; M Kimoto Journal: Biochem Biophys Res Commun Date: 1999-06-16 Impact factor: 3.575
Authors: Brad H Rovin; Huijuan Song; Dan J Birmingham; Lee A Hebert; Chack Yung Yu; Haikady N Nagaraja Journal: J Am Soc Nephrol Date: 2004-12-15 Impact factor: 10.121
Authors: A Sica; J M Wang; F Colotta; E Dejana; A Mantovani; J J Oppenheim; C G Larsen; C O Zachariae; K Matsushima Journal: J Immunol Date: 1990-04-15 Impact factor: 5.422
Authors: D J Stearns-Kurosawa; S Kurosawa; J S Mollica; G L Ferrell; C T Esmon Journal: Proc Natl Acad Sci U S A Date: 1996-09-17 Impact factor: 11.205
Authors: E M Tan; A S Cohen; J F Fries; A T Masi; D J McShane; N F Rothfield; J G Schaller; N Talal; R J Winchester Journal: Arthritis Rheum Date: 1982-11
Authors: Jan J Weening; Vivette D D'Agati; Melvin M Schwartz; Surya V Seshan; Charles E Alpers; Gerald B Appel; James E Balow; Jan A Bruijn; Terence Cook; Franco Ferrario; Agnes B Fogo; Ellen M Ginzler; Lee Hebert; Gary Hill; Prue Hill; J Charles Jennette; Norella C Kong; Philippe Lesavre; Michael Lockshin; Lai-Meng Looi; Hirofumi Makino; Luiz A Moura; Michio Nagata Journal: Kidney Int Date: 2004-02 Impact factor: 10.612
Authors: H A Austin; L R Muenz; K M Joyce; T A Antonovych; M E Kullick; J H Klippel; J L Decker; J E Balow Journal: Am J Med Date: 1983-09 Impact factor: 4.965
Authors: Daniel J Birmingham; Michael Merchant; Sushrut S Waikar; Haikady Nagaraja; Jon B Klein; Brad H Rovin Journal: Nephrol Dial Transplant Date: 2017-01-01 Impact factor: 5.992
Authors: Heather N Reich; Carol Landolt-Marticorena; Paul C Boutros; Rohan John; Joan Wither; Paul R Fortin; Stuart Yang; James W Scholey; Andrew M Herzenberg Journal: J Mol Diagn Date: 2011-03 Impact factor: 5.568
Authors: Peter M Izmirly; Marianna Shvartsbeyn; Shane Meehan; Andrew Franks; Alan Braun; Ellen Ginzler; Sherry X Xu; Herman Yee; Tania L Rivera; Tania Rivera; Charles Esmon; Laura Barisoni; Joan T Merrill; Jill P Buyon; Robert M Clancy Journal: J Rheumatol Date: 2012-02-01 Impact factor: 4.666
Authors: Evan Der; Saritha Ranabothu; Hemant Suryawanshi; Kemal M Akat; Robert Clancy; Pavel Morozov; Manjunath Kustagi; Mareike Czuppa; Peter Izmirly; H Michael Belmont; Tao Wang; Nicole Jordan; Nicole Bornkamp; Janet Nwaukoni; July Martinez; Beatrice Goilav; Jill P Buyon; Thomas Tuschl; Chaim Putterman Journal: JCI Insight Date: 2017-05-04
Authors: Harmony R Reynolds; Jill Buyon; Mimi Kim; Tania L Rivera; Peter Izmirly; Paul Tunick; Robert M Clancy Journal: Atherosclerosis Date: 2009-12-16 Impact factor: 5.162
Authors: Paul Hoover; Evan Der; Celine C Berthier; Arnon Arazi; James A Lederer; Judith A James; Jill Buyon; Michelle Petri; H Michael Belmont; Peter Izmirly; David Wofsy; Nir Hacohen; Betty Diamond; Chaim Putterman; Anne Davidson Journal: Arthritis Care Res (Hoboken) Date: 2020-01-13 Impact factor: 4.794